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poptosis after growth factor withdrawal or drug
treatment is associated with mitochondrial cyto-
chrome 
 
c
 
 release and activation of Apaf-1 and cas-
pase-9. To determine whether loss of Apaf-1, caspase-2,
and caspase-9 prevented death of factor-starved cells,
allowing them to proliferate when growth factor was re-
turned, we generated IL-3–dependent myeloid lines from
gene-deleted mice. Long after growth factor removal, cells
lacking Apaf-1, caspase-9 or both caspase-9 and caspase-2
appeared healthy, retained intact plasma membranes, and
did not expose phosphatidylserine. However, release of
A
 
cytochrome 
 
c
 
 still occurred, and they failed to form clones
when IL-3 was restored. Cells lacking caspase-2 alone had
no survival advantage. Therefore, Apaf-1, caspase-2, and
caspase-9 are not required for programmed cell death of
factor-dependent cells, but merely affect its rate. In contrast,
transfection with Bcl-2 provided long-term, clonogenic
protection, and could act independently of the apoptosome.
Unlike expression of Bcl-2, loss of Apaf-1, caspase-2, or
caspase-9 would therefore be unlikely to enhance the
survival of cancer cells.
 
Introduction
 
During apoptosis of mammalian cells after removal of serum
or growth factors, proteins such as cytochrome 
 
c
 
 and Diablo/
Smac are released from the mitochondria, apoptosomes
containing Apaf-1 and caspase-9 are formed, and effector
caspases become active and cleave their substrates. Apoptosis
due to growth factor withdrawal can usually be inhibited by
Bcl-2 (Vaux et al., 1988).
Programmed cell death in the worm 
 
Caenorhabditis elegans
 
has many similarities. It requires direct binding of the
Apaf-1–like adaptor protein CED-4 to the caspase CED-3
(Chinnaiyan et al., 1997; Irmler et al., 1997; Seshagiri and
Miller, 1997), and does not occur in worms with a gain
of function mutation of the Bcl-2 homologue CED-9
(Hengartner and Horvitz, 1994). CED-9 interacts directly
with CED-4 to inhibit apoptosis (Spector et al., 1997).
These observations suggested that Apaf-1 and caspase-9
might be essential for cell death in mammals, just as CED-4
and CED-3 are in the worm, and that Bcl-2 would prevent
apoptosis in mammals by directly binding to and inhibiting
Apaf-1 just as CED-9 binds to and inhibits CED-4.
However, this simple scheme is complicated by the finding
that neither Bcl-2 nor Bcl-x binds to Apaf-1 (Moriishi et al.,
1999). Furthermore, although most mice lacking genes for
Apaf-1 or caspase-9 die in the perinatal period due to neuronal
overgrowth, some develop normally and reproduce (Cecconi
et al., 1998; Hakem et al., 1998; Kuida et al., 1998; Yoshida
et al., 1998). These experiments, and those showing that
programmed cell death of lymphoid cells occurs normally
in Apaf-1– and caspase-9–deficient mice (Marsden et al.,
2002), raised the possibility that another caspase, such as
caspase-2 (Lassus et al., 2002) may compensate to cause
apoptosis in the absence of caspase-9.
We wished to determine whether myeloid cells undergo
apoptosis normally in the absence of Apaf-1 and caspase-9,
and if so whether also deleting caspase-2 would prevent cell
death. In addition, we wanted to test whether Bcl-2 could
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function in the absence of the apoptosome and caspase-2.
For the apoptotic stimulus we first used growth factor with-
drawal because it does not depend on direct toxic effects as
do chemotherapeutic drugs or irradiation, and can readily be
reversed by readdition of growth factor. We then tested
whether these observations also applied when apoptosis was
induced by the chemotherapeutic agents etoposide and
doxorubicin.
IL-3–dependent myeloid cell lines were established from
 
Apaf-1
 
 
 
 
 
/
 
 
 
, 
 
caspase-9
 
 
 
 
 
/
 
 
 
, 
 
caspase-2 
 
 
 
/
 
 
 
, and 
 
caspase-9 
 
 
 
/
 
 
 
;
 
caspase-2
 
 
 
 
 
/
 
 
 
 mice, and were tested in both short-term cell
death assays as well as clonogenic survival assays to see
whether any apparent survival advantage conferred by the
absence of Apaf-1 or caspases would allow cells to proliferate
when IL-3 was restored. To test whether Bcl-2 requires
Apaf-1, caspase-9, or caspase-2 to function, we enforced sta-
ble expression of Bcl-2. We found that, although cells lack-
ing Apaf-1, caspase-9 or both caspase-9 and caspase-2
appeared protected from apoptosis induced by IL-3 with-
drawal or cytotoxic drugs, there was no enhancement of clo-
nogenic survival over wild-type cells unless Bcl-2 was also
overexpressed. Our data suggest Apaf-1 and caspase-9 are re-
quired for rapid, efficient apoptosis but not for commitment
to cell death and that loss of Apaf-1 or caspase-9 does not
enhance long-term survival of cells.
 
Results
 
Cell death is delayed in Apaf-1 
 
 
 
/
 
 
 
, caspase-9 
 
 
 
/
 
 
 
, and 
caspase-9 
 
 
 
/
 
 
 
; caspase-2 
 
 
 
/
 
 
 
 IL-3–dependent cell lines
 
Growth factor withdrawal-induced apoptosis can be blocked
by Bcl-2 (Vaux et al., 1988), and is associated with release of
cytochrome 
 
c
 
 from mitochondria, and sequential activation
of Apaf-1 and caspase-9 (Hakem et al., 1998; Kuida et al.,
1998; Yoshida et al., 1998). To investigate the requirement
for Apaf-1, caspase-2, and caspase-9 in growth factor with-
drawal-induced cell death, we generated multiple, indepen-
dently derived, clonal, IL-3–dependent, promyeloid cell lines
from mice lacking either 
 
Apaf-1, caspase-2
 
, 
 
caspase-9
 
, or both
 
caspase-2
 
 and 
 
caspase-9
 
. These lines were produced by trans-
forming E14 fetal liver cells with a Hox 2.4 expressing retro-
virus in the presence of high amounts of IL-3, as described
previously (Perkins and Cory, 1993). Individual clones se-
lected from soft agar were maintained in liquid culture in the
presence of IL-3, and absence of the relevant proteins was
confirmed by Western blot (Fig. 1 G and not depicted).
When cultured in the absence of IL-3, many more 
 
Apaf-1
 
 
 
/
 
 
 
, 
 
caspase-9
 
 
 
 
 
/
 
 
 
, and 
 
caspase-9 
 
 
 
/
 
 
 
; 
 
caspase-2
 
 
 
 
 
/
 
 
 
 cells ap-
peared alive at each time point when viability was deter-
mined by exclusion of propidium iodide (PI; Fig. 1). Al-
though there was some variation between individual clones,
the wild-type and 
 
caspase-2 
 
 
 
/
 
 
 
 cells died significantly more
rapidly than the 
 
Apaf-1
 
 
 
 
 
/
 
 
 
, 
 
caspase-9
 
 
 
 
 
/
 
 
 
, and 
 
caspase-9 
 
 
 
/
 
 
 
;
 
caspase-2 
 
 
 
/
 
 
 
 double knockout cells and 
 
caspase-2 
 
 
 
/
 
 
 
 cells
even more rapidly than wild-type cells. Nevertheless, it was
also clear that even in the absence of Apaf-1 or caspase-9
some cells died over the 10-d duration of the experiments.
These data show that in the absence of Apaf-1 or caspase-9
 
 
 
10 times more cells survived when viability was measured
by uptake of PI.
To determine whether apoptosis in response to IL-3 with-
drawal involved Fas ligand signaling as has been reported
previously (Le-Niculescu et al., 1999), wild-type cells were
incubated in the presence or absence of IL-3 and an anti-
body that blocked mouse Fas ligand signaling (Fig. 1 H). Fas
ligand treated Jurkat cells (and SKW6 cells; unpublished
data) were used as a control to demonstrate the antibody
could inhibit Fas ligand induced apoptosis. When IL-3 was
removed, the same percentage of cells were Annexin V posi-
Figure 1. Deficiency of Apaf-1, caspase-9, or both caspase-9 and 
caspase-2 provides short-term protection against IL-3 withdrawal. 
Multiple independent clones of wild-type (A), Apaf-1 
 /  (B), cas-
pase-9 
 /  (C), caspase-2 
 /  (E), or caspase-9 
 / ; caspase-2 
 /  (D) 
IL-3–dependent cell lines were cultured in the absence of IL-3 and 
viability determined at the indicated times by propidium iodide (PI) 
exclusion using flow cytometry. The values represent the means of n 
independent clones in two to three independent experiments.
(F) The pooled arithmetic means   2 SEM of clones of each 
genotype is shown. (G) Western blot of representative clones of 
each of wild-type, Apaf-1 
 / , and caspase-9 
 / , caspase-2 
 / , and 
caspase-9 
 / ; caspase-2 
 /  cell lines. Probing with antibody to 
Heat shock protein 70 (Hsp 70) was used as a loading control. 
(H) Wild-type IL-3–dependent cells (open bars) were cultured in the 
presence or absence of IL-3 and a mouse-specific Fas ligand blocking 
antibody. Closed bars show Jurkat cells with and without mouse Fas 
ligand and the Fas ligand blocking antibody. Viability was determined 
by Annexin V expression and PI exclusion by flow cytometry. The 
results for wild-type IL-3–dependent cells show the mean of two 
independent clones in three independent experiments and the results 
for Jurkat cells shows the mean of an experiment done in triplicate. 
Error bars are SEM. 
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tive and/or had lost membrane integrity in the presence or
absence of the blocking antibody, indicating death after IL-3
withdrawal does not require Fas ligand signaling in these
cells. Furthermore, IL-3–dependent FDC-PI cells resistant
to Fas-induced apoptosis because they overexpress the viral
caspase-8 inhibitor crmA or a dominant negative FADD
construct, were equally sensitive to IL-3 withdrawal as were
wild-type cells, whereas cells overexpressing Bcl-2 were pro-
tected (Fig. S1, available at http://www.jcb.org/cgi/content/
full/jcb.200312031/DC1).
 
Many of the signs of apoptosis do not manifest in cells 
lacking Apaf-1 or caspase-9
 
Fig. 2 A shows the microscopic appearance of the cells 24 h
after growth factor withdrawal. Although many of the wild-
type and 
 
caspase-2 
 
 
 
/
 
 
 
 cells were shrunken and displayed
plasma membrane blebbing, the 
 
Apaf-1 
 
 
 
/
 
 
 
, 
 
caspase-9 
 
 
 
/
 
 
 
,
and 
 
caspase-9 
 
 
 
/
 
 
 
; caspase-2 
 
 
 
/
 
 
 
 cells looked as healthy as the
cells cultured with factor. Less 
 
Apaf-1 
 
 
 
/
 
 
 
, 
 
caspase-9 
 
 
 
/
 
 
 
, and
 
caspase-9 
 
 
 
/
 
 
 
; caspase-2 
 
 
 
/
 
 
 
 cells exposed phosphatidylserine
on the membrane surface as indicated by Annexin V staining
(unpublished data). Western blots of lysates from wild-type,
 
Apaf-1 
 
 
 
/
 
 
 
, 
 
caspase-9 
 
 
 
/
 
 
 
, and 
 
caspase-9 
 
 
 
/
 
 
 
; caspase-2 
 
 
 
/
 
 
 
cells (Fig. 3) showed that much more caspase-3, caspase-7
and ICAD processing occurred in wild-type cells than in
those lacking Apaf-1 or caspase-9. These data suggest that
many of the morphological changes associated with apopto-
sis in response to growth factor withdrawal are dependent on
caspase-9 and Apaf-1. This appears to be cell type–depen-
dent because thymocytes from 
 
Apaf-1 
 
 
 
/
 
 
 
 and 
 
caspase-9 
 
 
 
/
 
 
Figure 2. After 24 h without IL-3, Apaf-1 
 / , caspase-9 
 / , and caspase-9 
 / ; caspase-2 
 /  cells appear 
healthy, exclude PI but have released cytochrome c from 
mitochondria. (A) Light microscopy of cells cultured with 
or without IL-3 for the indicated genotype. Wild-type and 
caspase-2 
 /  cells show similar changes, with marked 
cell shrinkage and loss of refractivity whereas Apaf-1 
 / , 
caspase-9 
 / , and caspase-9 
 / ; caspase-2 
 /  cells 
appear healthy. (B) PI uptake determined by flow cytometry. 
Increasing fluorescence (FL-3 channel) indicates PI uptake 
by cells that have lost membrane integrity. The majority 
of Apaf-1 
 / , caspase-9 
 / , and caspase-9 
 / ; caspase-2 
 /  cells exclude PI 24 h after withdrawal of IL-3. (C) Intra-
cellular cytochrome c staining assessed by flow cytometry 
(FL-1 channel). Loss of cytochrome c from mitochondria is 
indicated by a shift of fluorescence to the left. Apaf-1 
 / , 
caspase-9 
 / , and caspase-9 
 / ; caspase-2 
 /  cells lose 
cytochrome c like wild-type and caspase-2 
    cells, 
despite excluding PI. Bcl-2 overexpression (shown here 
in Bcl-2; caspase-9 
 /  cells) prevents cytochrome c 
release. Multiple clones of cells of all genotypes were 
examined with and without IL-3, and typical results are 
shown.838 The Journal of Cell Biology | Volume 165, Number 6, 2004
mice showed DNA degradation, caspase-7, PARP and ICAD
processing, as well as cleavage of a fluorogenic caspase sub-
strate in response to various apoptotic stimuli; although in
most instances, this was reduced compared with that ob-
served in control cells (Marsden et al., 2002).
To determine whether cytochrome c was still released in
the absence of Apaf-1 or caspase-9, we stained plasma mem-
brane–permeabilized, IL-3–starved cells with an antibody to
cytochrome c and analyzed the cells by flow cytometry. As
shown in Fig. 2 C, although cells lacking Apaf-1 or caspase-9
appeared normal when growth factor was removed, cyto-
chrome c had been released from the mitochondria.
These data show that the downstream events associated
with caspase-9 activation are greatly reduced in factor-
starved Apaf-1 
 / , caspase-9 
 / , and caspase-9 
 / ; caspase-2
 /  cells, just as they were in Apaf-1 
 /  and caspase-9 
 / 
MEFs (Cecconi et al., 1998; Hakem et al., 1998). However,
the fact that cytochrome c was still released from the IL-3
deprived Apaf-1 
 /  and caspase-9 
 /  cells made us question
whether they were still committed to die, despite their
healthy appearance.
Short-term survival of Apaf-1 
 /  and caspase-9 
 /  cells 
does not translate into long-term, clonogenic survival
To determine whether the survival advantage of Apaf-1 
 / 
and caspase-9 
 /  cells observed after IL-3 withdrawal would
also permit long-term survival, thereby allowing more cells
to proliferate when cytokine was returned, we starved cells of
IL-3 for increasing time periods and then transferred them
to soft agar with abundant growth factor, and counted the
number of colonies that formed (Fig. 4). Factor-starved
Apaf-1 
 / , caspase-9 
 / , or caspase-9 
 / ; caspase-2 
 /  dou-
ble knockout lines were no more able to generate colonies
than wild-type cells when transferred to soft agar with IL-3
(Fig. 4 B), even though 10-fold more Apaf-1 
 /  and caspase-
9 
 /  cells excluded PI at the time they were plated in agar
(Fig. 4 A). These results show that although the absence of
Apaf-1 or caspase-9 significantly delays certain morphologi-
cal changes associated with apoptosis, these lines were not
growth factor independent, and were normally committed
to programmed cell death when IL-3 was withdrawn.
The fact that caspase-9 
 /  myeloid and lymphoid cells
(Marsden et al., 2002) can still undergo programmed cell
death raised the possibility that another caspase was respon-
sible. Although evidence from RNA interference experi-
ments suggested that this might be caspase-2 (Lassus et al.,
2002), our experiments on caspase-2 
 /  and caspase-9 
 / ;
caspase-2 
 /  cells revealed no role for caspase-2 in cell death
in either short or long-term clonogenic survival assays, or
any redundancy with caspase-9 (Figs. 1, 2, and 4).
Bcl-2 promotes clonogenic survival of Apaf-1 
 /  
and caspase-9 
 /  cells
Because Bcl-2 has been shown to promote clonogenic sur-
vival of growth factor–deprived cells, we tested whether it
could still do so in the absence of Apaf-1 or caspase-9. Mul-
tiple independent clones were established that stably overex-
Figure 3. Diminished caspase activity in IL-3–starved Apaf-1 
 / , 
caspase-9 
 / , and caspase-9 
 / ; caspase-2 
 /  cells. Lysates from 
cells cultured in the presence or absence of IL-3 over a 3-d period 
were separated by SDS PAGE on 4–20% gradient gels and immuno-
blotted with antibodies to the indicated proteins. Activation of 
caspase-3 and caspase-7 is indicated by the loss of the full-length 
protein and, in the case of caspase-7, by the appearance of the 
processed p10 fragment. The cleavage of ICAD is indicated by the 
loss of the full-length protein. The ICAD cleavage fragment could 
not be observed. Levels of Hsp70 are shown as a loading control.
Figure 4. Apaf-1 
 / , caspase-9 
 / , and caspase-9 
 / ; caspase-2 
 /  cells are committed to die after IL-3 withdrawal. Wild-type, 
Apaf-1 
 / , caspase-9 
 / , caspase-2 
 / , and caspase-9 
 / ; cas-
pase-2 
 /  cells were cultured in the presence (solid line) or ab-
sence (dashed line) of IL-3 for the indicated times. (A) Analysis of PI 
exclusion at each time point with and without growth factor. (B) 
Varying dilutions of cells were cultured in soft agar with abundant
IL-3 after the indicated period of IL-3 deprivation, and the number 
of colonies formed was counted after 21 d. The y axis indicates the 
number of colony forming units per 1,000 cells originally plated. 
Values shown are the means of at least two independent clones 
for each genotype from four independent experiments. Error bars 
are   SEM.Apaf-1 and caspase-9 accelerate apoptosis | Ekert et al. 839
press Bcl-2 (confirmed by Western blot; Fig. 5). When these
cells were cultured in the absence of IL-3, and their viability
determined by exclusion of PI, Bcl-2 was able to increase
survival of wild-type, Apaf-1 
 / , and caspase-9 
 /  cells (Fig.
5 A). Furthermore, in Bcl-2 overexpressing lines derived
from the same gene-deleted parental clones, we found that
Bcl-2 promoted clonogenic survival after IL-3 withdrawal
(Fig. 5 B). These results show that Bcl-2 can prevent cell
death, and can do so independently of Apaf-1 or caspase-9,
which is consistent with its ability to prevent cytochrome c
release from the mitochondria (Fig. 2 C, bottom).
Apaf-1 
 /  and caspase-9 
 / ; caspase-2 
 /  cells show 
short-term resistance to cytotoxic drugs but not 
clonogenic survival
Some cell types from Apaf-1 
 /  and caspase-9 
 /  animals
showed typical apoptotic morphology in response to a range
of death stimuli, including cytotoxic drugs (Marsden et al.,
2002). To determine whether the short-term protection of
the cell lines depended on the death stimulus used, we
treated Apaf-1 
 /  and caspase-9 
 / ; caspase-2 
 /  cells with
etoposide or doxorubicin and determined viability after 24 h
(Fig. 6). Compared with wild-type cells, both Apaf-1 
 / 
and caspase-9 
 / ; caspase-2 
 /  cells survived treatment with
these agents as determined by Annexin V-Fluos/PI uptake
(Fig. 6, A and C). This result was similar to that observed af-
ter IL-3 withdrawal. To determine whether this short-term
protection translated into clonogenic survival, the cells were
plated in soft agar after washing the drug from the culture
Figure 5. Expression of Bcl-2 provides protection against IL-3 
withdrawal-induced apoptosis and promotes clonogenic survival. 
Cells of the indicated genotype containing either empty vector (pEF) 
or Bcl-2 expression construct were cultured in the absence of IL-3 
for the indicated times. (A) Viability determined by PI exclusion 
using flow cytometry. (B) Varying dilutions of cells were cultured in 
soft agar with abundant IL-3 following the indicated period of IL-3 
deprivation and the number of colonies formed counted after 21 d. 
The y axis represents the number of colony forming units per 1,000 
cells originally plated. Western blots show the levels of Bcl-2 
expression in the cell lines that were examined (five representative 
wild-type lines are shown). The value n represents the number of 
independent clones tested for each genotype. The values shown are 
the means   SEM from three independent experiments.
Figure 6. Apaf-1 
 /  and caspase-9 
 / ; caspase-2 
 /  cells appear 
viable when treated with etoposide or doxorubicin, but are com-
mitted to die. Wild-type, Apaf-1 
 / , and caspase-9 
 / ; caspase-2 
 /  cells were treated with the indicated doses of etoposide (A and B) 
or doxorubicin (C and D) for 24 h. Viability was determined by 
Annexin V staining and PI exclusion using flow cytometry (A and C), 
and clonogenic survival was determined by plating in soft agar and 
counting the number of colonies after 21 d (B and D). The viability 
curves show the mean   SEM of two independent clones of each 
genotype in three independent experiments. The clonal assays show 
mean   SEM of two independent clones of each genotype in two 
independent experiments.840 The Journal of Cell Biology | Volume 165, Number 6, 2004
(Fig. 6, B and D). Apaf-1 
 /  and caspase-9 
 / ; caspase-2 
 / 
cells were no more able to form colonies than wild-type cells,
even though many more Apaf-1 
 /  and caspase-9 
 / ; cas-
pase-2 
 /  cells appeared viable. These data show that, as
was the case in IL-3 withdrawal induced apoptosis, the ab-
sence of Apaf-1 or caspase-9 delayed certain morphological
changes associated with apoptosis, but these lines neverthe-
less remained committed to programmed cell death after
treatment with cytotoxic drugs.
Discussion
Although either too much or too little apoptosis has been as-
sociated with a multiplicity of diseases, the clearest example
where abnormalities of apoptosis are primary and causative
is in the case of certain cancers. Translocations involving the
bcl-2 gene in follicular lymphoma led to the identification of
Bcl-2 (Tsujimoto et al., 1984, 1985), and its recognition as
the first component of the apoptosis mechanism (Vaux et
al., 1988). Transgenic mice expressing Bcl-2 formally con-
firmed that inhibition of cell death could lead to the devel-
opment of cancer (Strasser et al., 1990).
Correlative evidence also exists implicating other compo-
nents of the apoptotic mechanism in cancer. For example,
loss of expression of Apaf-1 has been associated with mela-
noma, Apaf-1 has been reported to be required for apoptosis
triggered by the tumor suppressor gene p53 (Soengas et al.,
1999, 2001), and expression of the caspase inhibitory IAP
protein ML-IAP has been associated with melanoma (Vucic
et al., 2000).
Development of a cancer requires the survival of a clone of
cells capable of further reproduction. For an apoptosis in-
hibitor to enhance tumor development, it must allow cells to
retain their clonogenic potential. Bcl-2, which acts upstream
of the mitochondria, can promote clonogenic protection.
We wished to determine whether inhibiting events down-
stream of the mitochondria, such as activation of caspase-9
by Apaf-1, would also promote long-term clonogenic sur-
vival. By testing IL-3–dependent cell lines lacking genes for
Apaf-1 or caspase-9 and transfecting them with Bcl-2, we
also sought to determine whether Bcl-2 could act indepen-
dently of Apaf-1.
Unlike Marsden et al. (2002), who found that lymphoid
cells underwent apoptosis relatively normally in the absence
of Apaf-1 or caspase-9, we found that the appearance of clas-
sical hallmarks of apoptosis, including exposure of phos-
phatidylserine, membrane blebbing, cleavage of caspases and
their substrates, and uptake of PI, were markedly delayed in
myeloid cells lacking Apaf-1 or caspase-9. Nevertheless, ab-
sence of Apaf-1 or caspase-9 did not increase the number of
surviving cells that could form clones after IL-3 was restored,
indicating that in these cells Apaf-1 and caspase-9 act after
the cell death commitment point to enhance the rate of cell
demolition, but that these molecules do not determine
whether cells will ultimately die. These experiments illus-
trate the critical importance of clonal assays in cell death re-
search, because measuring cell death by morphology, uptake
of vital dyes, exposure of phosphatidylserine, activation of
caspases or cleavage of their substrates, will not necessarily
reveal whether a cell is committed to die.
Overexpressing Bcl-2 in the Apaf-1 and caspase-9 null cells
demonstrated that Bcl-2 requires neither Apaf-1 nor cas-
pase-9 to function, and acts before the commitment point,
to provide clonogenic protection. The ability of Bcl-2 to
provide clonal protection independently of Apaf-1 and cas-
pase-9 in factor-dependent cells responding to a physiologi-
cal death stimulus extends earlier work showing that Bcl-2
was capable of giving short- and long-term protection to
Apaf-1 null embryonic stem cells treated with chemothera-
peutic agents (Haraguchi et al., 2000). Furthermore, defi-
ciency of either Apaf-1 or caspase-9 did not enhance lym-
phomagenesis in c-myc transgenic mice, nor contribute to
oncogenic transformation of fibroblasts (Scott et al., 2004).
Collectively, these observations question the ability of Apaf-1
or caspase-9 to act as tumor suppressor genes.
Deletion of caspase-2 did not inhibit cytochrome c release
from mitochondria or confer any short- or long-term sur-
vival advantage, suggesting caspase-2 is not required for
apoptosis resulting from growth factor withdrawal in our
cell lines. Indeed, caspase-2 
 /  lines on average exhibited ap-
optotic changes even more rapidly than wild-type lines in re-
sponse to growth factor withdrawal. If the presence of cas-
pase-2 does somehow delay appearance of some of the
markers of apoptosis, this is unlikely to be physiologically
important, because caspase-2 
 /  cells commit to die at the
same rate as wild-type cells as revealed by clonogenic assays,
and caspase-2 
 /  mice are indistinguishable from wild-type
or heterozygous littermate controls (O’Reilly et al., 2002).
There have been suggestions that Fas ligand signaling con-
tributes to death of neuronal cells after withdrawal of a sur-
vival factor (KCl; Le-Niculescu et al., 1999). In IL-3–depen-
dent myeloid lines, a Fas-ligand blocking antibody did not
reduce apoptosis after IL-3 withdrawal. Furthermore, IL-3–
dependent FDC-P1 cells overexpressing a FADD dominant
negative construct or crmA remained as susceptible to IL-3
withdrawal as control cells (Fig. S1), indicating no role for
Fas ligand in growth factor withdrawal-induced apoptosis.
Although these experiments show that Bcl-2 can provide
long-term clonogenic protection, they do not reveal how it
acts. Several possibilities present themselves. The cells lack-
ing Apaf-1 might have died from inadequate mitochondrial
respiratory function (Gottlieb et al., 2002); they may have
died as a result of substrate deprivation and autophagy; or
they might have died because of activation of caspases that
do not require Apaf-1 for their activation. In the first two
scenarios Bcl-2 would protect the cells by preventing cyto-
chrome c release or in some way maintaining mitochondrial
respiratory function, whereas in the third possibility Bcl-2
would protect the cells by preventing caspase activation.
Materials and methods
Cell lines and culture
Apaf-1 
 /  (gift from F. Cecconi, Universita Tor Vergata, Rome, Italy, and
P. Gruss, Max Planck Institute of Biophysical Science, Göttingen, Ger-
many) and caspase-9 
 /  mice (gift from K. Kuida, Genomic Pharmacol-
ogy, Vertex Pharmaceuticals, Cambridge, MA; 3450; Cecconi et al., 1998;
Kuida et al., 1998) originally derived from 129/sv ES cells and backcrossed
over 10 times to C57BL/6, caspase-2 
 /  mice (129/sv; O’Reilly et al.,
2002), offspring of intercrossed caspase-9 
 /  and caspase-2 
 /  mice, and
their wild-type littermates, were used as sources of fetal liver for produc-
tion of IL-3–dependent cell lines as described previously (Perkins andApaf-1 and caspase-9 accelerate apoptosis | Ekert et al. 841
Cory, 1993). In brief, suspensions of E14 fetal liver from wild-type, Apaf-1
 / , caspase-9 
 / , caspase-2 
 / , and caspase-9 
 / ; caspase-2 
 /  embryos
were cocultured with cells expressing a Hox 2.4 retrovirus in the presence
of a high concentration of IL-3 containing supernatant (5–10%) derived
from an IL-3–producing hybridoma cell line. This promotes the conditional
immortalization of IL-3–dependent promyeloid lines. After 5 d, nonadher-
ent cells were cultured in soft agar and then a further 10–14 d later com-
pact colonies were individually selected and put back into liquid culture
containing IL-3. Rarely, a cell line would differentiate after 2–3 wk in cul-
ture (indicated by changed morphology and becoming adherent). Such
lines were not used. Each line was tested for IL-3 dependence as indicated
by inhibition of proliferation in the absence of IL-3. No clones that main-
tained a suspension phenotype but continued to proliferate in the absence
of IL-3 were encountered. Cells were maintained in DME supplemented
with 10% FCS and 3% IL-3 supernatant.
Plasmids and transfection
To generate cells expressing empty vector or Bcl-2, 10
7 cells were washed
in balanced salt solution and then resuspended in 400  l of balanced salt
solution and 20% FCS, and electroporated with 10–15  g of either empty
pEF vector or pEF containing a human Bcl-2 construct (Huang et al., 1997)
linearized with Fsp-1 (New England Biolabs, Inc.). Cells were then divided
into three aliquots (to ensure independent clones) and cultured in soft agar
with 3  g/ml puromycin. After 2–3 weeks, puromycin resistant colonies
were selected and tested for Bcl-2 expression by flow cytometry as de-
scribed previously (Ekert et al., 1999) and by Western blot.
Clonal assays and viability
To assay IL-3 withdrawal induced cell death, cells were washed and sus-
pended in IL-3–deficient media at a density of 10
6 cells/ml and plated in
200  l aliquots in 96 well plates. Cell viability was determined by PI ex-
clusion using flow cytometry (Becton Dickinson). In assays using etoposide
or doxorubicin, cells were plated at a density of 10
5 cells/ml in 48 well
plates in normal growth media. Drug was added at the indicated doses. Af-
ter 24 h, a 100- l aliquot was used to determine viability by Annexin
V-Fluos/PI staining (Roche) as described in the manufacturer’s protocol.
The remainder of the culture was used in a clonogenic assay (see below).
Fas ligand was generated as described previously (Knight et al., 2001).
Jurkat cells were treated with Fas ligand at a 1:20 dilution for 6 or 24 h. A
blocking antibody (mouse monoclonal anti-Fas ligand antibody; clone
3C82; Qbiogene) was used at 5  g/ml.
For clonal assays, cells were washed twice in PBS and then plated at a
density of 2   10
4 or 5   10
4 with or without IL-3 in 1 ml of media in 24
well plates. Separate wells were harvested at each time point. At the indi-
cated times, the cells were removed, counted, viability determined by PI
uptake by flow cytometry and various dilutions plated in soft agar. After 21 d,
the number of colonies was counted and the number of colony forming
units per 1,000 cells plated at time 0 calculated. For clonal assays using
cytotoxic drugs, 500  l (half) of the culture was washed in 10 ml of DME
and the cells then resuspended in 500  l of normal media. 25 and 250  l
of each culture was plated in soft agar and the number of colonies counted
at 21 d as before.
Cell lysis and Western blotting
Cells were lysed in 50 mM Tris-HCl, pH 7.5, 1% SDS, 0.5 mM EDTA, 1
mM DTT, and immediately boiled for 10 min. The lysate was then centri-
fuged at 13,000 rpm and the supernatant diluted 1:5 in RIPA buffer plus
protease inhibitors. Lysates were run either on precast 4–20% gradient gels
or 10% gels (Gradipore) and then transferred to nitrocellulose (Hybond-N).
The antibodies used were: mouse-specific anti–caspase-9 (Cell Signaling),
mouse monoclonal anti–caspase-7 (a gift from Y. Lazebnik, Cold Spring
Harbor Laboratory, Cold Spring Harbor, NY), anti–caspase-3 (Cell Signal-
ing), rat monoclonal anti–Apaf-1 (clone 18H2; gift from L. O’Reilly, Walter
and Eliza Hall Institute for Medical Research), mouse anti–human Bcl-2
(DakoCytomation), rabbit anti–mouse ICAD (BD Biosciences), and anti–
Hsp-70 (gift from W. Welch and R. Anderson, Peter McCallum Cancer In-
stitute, Melbourne, Australia).
Intracellular cytochrome c staining
Cytochrome c release was assayed using a method described previously
(Waterhouse and Trapani, 2003). Cells cultured with and without IL-3
were washed in PBS and were resuspended in 200  l digitonin (120  g/
ml) in buffer (KCl 75 mM, sucrose 250 mM, NaH2PO4 1 mM, Na2HPO4 8
mM). After a 15-min incubation on ice, formaldehyde was added to a final
concentration of 4% in a total volume of 400  l and the cells were incu-
bated at RT for 1 h. They were then pelleted, washed in PBS, and resus-
pended in blocking buffer (3% BSA, 0.05% saponin in PBS) and tubes ro-
tated at 4 C for 1 h. Anti–cytochrome c antibody (BD Biosciences) was
added (1/200) and the cells were rotated overnight at 4 C. The cells were
pelleted, washed once in PBS and rotated in blocking buffer containing
1:100 of anti–mouse Ig G FITC (Amersham Biosciences) at 4 C for 1 h.
Cells were pelleted, washed once in PBS, and analyzed by flow cytometry
using a FACSCalibur (Becton Dickinson). Debris was excluded from analy-
sis by gating for intact cells using forward and side scatter parameters.
Image acquisition
Microscopy was performed on a microscope (model IX70; Olympus) using
Hoffmann differential contrast microscopy and a 40X objective. The image
was acquired using a SPOT camera (model 1.4.0; Diagnostic Instruments)
and SPOT software (version 2.2) and saved as TIFF files. The images were
imported into Freehand MX (Macromedia) for the compilation of the figure
(Fig. 2) and saved as a JPEG file.
Online supplemental material
In Fig. S1, FDC-P1 cells were stably transfected with pEF empty vector or
pEF vector containing human Bcl-2, dominant negative FADD, or crmA.
Cells were cultured in RPMI with 10% FCS and 0.1% IL-3 supernatant. For
IL-3 withdrawal experiments, cells were washed three times in PBS
and cultured in RPMI with 10% FCS over 3 d. Viability was determined
by PI uptake using flow cytometry. Four independent clones of each
construct were used in three independent experiments. Online supple-
mental material is available at http://www.jcb.org/cgi/content/full/jcb.
200312031/DC1.
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